Human Mannose-Binding Lectin Inhibitor Prevents Myocardial Injury and Arterial Thrombogenesis in a Novel Animal Model

Myocardial infarction and coagulation disorders are Leading causes of disability and death in the world. An important role of the Lectin complement pathway in myocardial infarction and coagulation has been demonstrated in mice genetically deficient in Lectin complement pathway proteins. However, these studies are Limited to comparisons between wild-type and deficient mice and Lack the ability to examine reversal/inhibition of injury after disease establishment. We developed a novel mouse that expresses functional human mannose-binding lectin (MBL) 2 under the control of Mbl1 promoter. Serum MBL2 concentrations averaged approximately 3 mu g/mL in MBL2(+/+)Mbl1(-/-) Mbl2(-/-) [MBL2 knock in (KI)] mice. Serum MBL2 Level in MBL2 KI mice significantly increased after 7 (8 mu g/mL) or 14 (9 mu g/mL) days of hyperglycemia compared to normoglycemic mice (P < 0.001). Monoclonal antibody 3F8 inhibited C3 deposition on mannan-coated plates in MBL2 KI, but not wild-type, mice. Myocardial ischemia/reperfusion in MBL2 KI mice revealed that 3F8 preserved cardiac function and decreased infarct size and fibrin deposition in a time-dependent manner. Furthermore, 3F8 prevented ferric chloride induced occlusive arterial thrombogenesis in vivo. MBL2 KI mice represent a novel animal model that can be used to study the Lectin complement pathway in acute and chronic models of human disease. Furthermore, these novel mice demonstrate the therapeutic window for MBL2 inhibition for effective treatment of disease and its complications.